HR
ADPT icon

Howe & Rusling’s Adaptive Biotechnologies ADPT Stock Holding History

Howe & Rusling’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14
Closed – – 1045
2022
Q2 		$0 Buy
+14
New +$123 ﹤0.01% 1045
2021
Q1 		– Sell
-25
Closed -$1K – 940
2020
Q4 		$1K Buy
+25
New +$1.29K ﹤0.01% 853

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Howe & Rusling's ADPT Position: Q3 2022 in Review

Howe & Rusling sold out of Adaptive Biotechnologies (ADPT) in Q3 2022, closing a stake of 14 shares.

Howe & Rusling first reported a position in ADPT in Q4 2020 and held it in 2 quarters. The position peaked at $1K in Q4 2020. 226 funds tracked by Wall St. Rank hold ADPT as of Q3 2022.

  • Howe & Rusling reported no remaining Adaptive Biotechnologies position as of Q3 2022 after selling out during the quarter.
  • Howe & Rusling sold 14 Adaptive Biotechnologies shares in Q3 2022.
  • Howe & Rusling first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 2 quarters.
  • Howe & Rusling's Adaptive Biotechnologies position peaked at $1K in Q4 2020.
  • 226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.